Other researchers have found that MAPK activation in ovarian cancer model tumor cells can drive hormone therapy resistance through ERα.[56] Therefore, MEKi and endocrine drugs may have a synergistic effect, and future clinical trials of MERi combined with AI are needed to further verify this.[59] In addition, a clinical trial of AI in combination with a cyclin-dependent kinase inhibitor (NCT03673124) is underway to evaluate the efficacy of letrozole and the CDK4/6 inhibitor, ribociclib, in relapsed LGSOC with measurable lesions. The gene discussed is ESR1; the disease is neoplasm.